Ironwood Pharmaceuticals Agrees To Acquire VectivBio For $17/Share In An All-Cash Transaction With An Estimated Aggregate Consideration Of Approximately $1B
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals has agreed to acquire VectivBio for $17/share in an all-cash transaction, with an estimated aggregate consideration of approximately $1 billion.
May 22, 2023 | 10:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ironwood Pharmaceuticals is acquiring VectivBio for $17/share in a $1 billion all-cash transaction.
The acquisition of VectivBio will likely have a positive impact on Ironwood Pharmaceuticals' stock price in the short term, as it expands the company's portfolio and strengthens its position in the pharmaceutical industry.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
VectivBio is being acquired by Ironwood Pharmaceuticals for $17/share in a $1 billion all-cash transaction.
The acquisition by Ironwood Pharmaceuticals will likely have a positive impact on VectivBio's stock price in the short term, as shareholders will receive a premium for their shares in the all-cash transaction.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100